Venous thromboembolism (VTE) in cancer patients. ESMO Clinical Recommendations for prevention and management

Thrombosis Research

Volumn 125, Issue , 2010, Pages S117-S119

  Mandalà, Mario ^a   Labianca, Roberto ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

Cancer; ESMO; Guidelines; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT;

ARTICLE; EUROPE; HEALTH CARE PLANNING; HUMAN; MEDICAL SOCIETY; NEOPLASM; PRACTICE GUIDELINE; RISK FACTOR; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; EUROPE; HEALTH PLANNING GUIDELINES; HUMANS; NEOPLASMS; RISK FACTORS; SOCIETIES, MEDICAL; VENOUS THROMBOEMBOLISM;

EID: 77955508620     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/S0049-3848(10)70028-1     Document Type: Article

References (16)

1. Cohen, AT, Agnelli, A, Anderson, FA, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Hemost 98 (2007), 756–764.
2. Kahn, SR, Ducruet, T, Lamping, DL, et al. Prospective evaluation of health-related quality of life in patients with deep venous thrombosis. Arch Intern Med 165 (2005), 1173–1178.
3. Khorana, AA, Francis, CW, Culakova, E, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5 (2007), 632–634.
4. Mandala, M, Barni, S, Floriani, I, et al. Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: the ‘GISCAD-alternating schedule’ study findings. Eur J Cancer 45 (2009), 65–73.
5. Cohen, AT, Tapson, VF, Bergmann, JF, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 371 (2008), 387–394.
6. Chew, HK, Wun, T, Harvey, D, Zhou, H, White, RH, Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166 (2006), 458–464.
7. Nalluri, SR, Chu, D, Keresztes, R, et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients. A meta-analysis. JAMA 300 (2008), 2277–2285.
8. Khorana, AA, Francis, CW, Culakova, E, et al. Thromboembolism in hospitalised neutropenia cancer patients. J Clin Oncol 24 (2006), 484–490.
9. Khorana, AK, Kunderer, NM, Culakova, E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111 (2008), 4902–4907.
10. Samama, MM, Cohen, AT, Darmon, JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients: Prophylaxis in medical patients with enoxaparin study group. N Engl J Med 341 (1999), 793–800.
11. Leizorovicz, A, Cohen, AT, Turpie, AG, et al. PREVENT Medical Thromboprophylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 110 (2004), 874–879.
12. Cohen, AT, Davidson, BL, Gallus, AS, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 332 (2006), 325–329.
13. Lee, AYY, Levin, M, Baker, R.I., et al. Low molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349 (2003), 146–153.
14. Hull, R, Pineo, GF, Brant, RF, et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 119 (2006), 1062–1072.
15. Meyer, G, Marjanovic, Z, Valcke, J, et al. Comparison of low-molecular-weight-heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 162 (2002), 1729–1735.
16. Carrier, M, Le Gal, G, Cho, R, Tierney, S, Rodger, M, Lee, AY, Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. J Thromb Haemost 7 (2009), 760–765.